These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33835939)

  • 1. Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO Study.
    Bushinsky DA; Raggi P; Bover J; Ketteler M; Bellasi A; Rodriguez M; Sinha S; Garg R; Perelló J; Gold A; Chertow GM; ;
    Clin J Am Soc Nephrol; 2021 May; 16(5):736-745. PubMed ID: 33835939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study.
    Raggi P; Bellasi A; Bushinsky D; Bover J; Rodriguez M; Ketteler M; Sinha S; Salcedo C; Gillotti K; Padgett C; Garg R; Gold A; Perelló J; Chertow GM
    Circulation; 2020 Mar; 141(9):728-739. PubMed ID: 31707860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification.
    Bellasi A; Raggi P; Bover J; Bushinsky DA; Chertow GM; Ketteler M; Rodriguez M; Sinha S; Salcedo C; Garg R; Gold A; Perelló J
    Clin Kidney J; 2021 Jan; 14(1):366-374. PubMed ID: 33564440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis.
    Brandenburg VM; Sinha S; Torregrosa JV; Garg R; Miller S; Canals AZ; Bahr D; Joubert PH; Salcedo C; Carroll KJ; Gold A; Perelló J
    J Nephrol; 2019 Oct; 32(5):811-821. PubMed ID: 31401795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial.
    Raggi P; Bellasi A; Sinha S; Bover J; Rodriguez M; Ketteler M; Bushinsky DA; Garg R; Perelló J; Gold A; Chertow GM
    Kidney Int Rep; 2020 Dec; 5(12):2178-2182. PubMed ID: 33305110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification.
    Perelló J; Joubert PH; Ferrer MD; Canals AZ; Sinha S; Salcedo C
    Br J Clin Pharmacol; 2018 Dec; 84(12):2867-2876. PubMed ID: 30280390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SNF472, a novel anti-crystallization agent, inhibits induced calcification in an in vitro model of human aortic valve calcification.
    Zabirnyk A; Ferrer MD; Bogdanova M; Pérez MM; Salcedo C; Kaljusto ML; Kvitting JP; Stensløkken KO; Perelló J; Vaage J
    Vascul Pharmacol; 2019; 122-123():106583. PubMed ID: 31437530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels.
    Perelló J; Gómez M; Ferrer MD; Rodríguez NY; Salcedo C; Buades JM; Pérez MM; Torregrosa JV; Martín E; Maduell F
    J Nephrol; 2018 Apr; 31(2):287-296. PubMed ID: 29350348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SNF472: mechanism of action and results from clinical trials.
    Sinha S; Raggi P; Chertow GM
    Curr Opin Nephrol Hypertens; 2021 Jul; 30(4):424-429. PubMed ID: 34027904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.
    Perelló J; Ferrer MD; Del Mar Pérez M; Kaesler N; Brandenburg VM; Behets GJ; D'Haese PC; Garg R; Isern B; Gold A; Wolf M; Salcedo C
    Br J Pharmacol; 2020 Oct; 177(19):4400-4415. PubMed ID: 32557649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial.
    Grey AB; Stapleton JP; Evans MC; Tatnell MA; Reid IR
    Ann Intern Med; 1996 Sep; 125(5):360-8. PubMed ID: 8702086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel assay to measure calcification propensity: from laboratory to humans.
    Perez MM; Ferrer MD; Lazo-Rodriguez M; Canals AZ; Banon-Maneus E; Campistol JM; Miller S; Garg R; Gold A; Salcedo C; Perelló J
    Sci Rep; 2020 Oct; 10(1):17578. PubMed ID: 33067536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineral bone disorder and osteoporosis in hemodialysis patients.
    Slouma M; Sahli H; Bahlous A; Laadhar L; Smaoui W; Rekik S; Gharsallah I; Sallami M; Moussa FB; Elleuch M; Cheour E
    Adv Rheumatol; 2020 Feb; 60(1):15. PubMed ID: 32102689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.
    Salcedo C; Joubert PH; Ferrer MD; Canals AZ; Maduell F; Torregrosa V; Campistol JM; Ojeda R; Perelló J
    Br J Clin Pharmacol; 2019 Apr; 85(4):796-806. PubMed ID: 30632182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis.
    Malluche HH; Davenport DL; Cantor T; Monier-Faugere MC
    Clin J Am Soc Nephrol; 2014 Jul; 9(7):1254-62. PubMed ID: 24948144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.
    Sköldenberg OG; Salemyr MO; Bodén HS; Ahl TE; Adolphson PY
    J Bone Joint Surg Am; 2011 Oct; 93(20):1857-64. PubMed ID: 22012522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association among serum fetuin-A level, coronary artery calcification, and bone mineral densitometry in maintenance hemodialysis patients.
    Kirkpantur A; Altun B; Hazirolan T; Akata D; Arici M; Kirazli S; Turgan C
    Artif Organs; 2009 Oct; 33(10):844-54. PubMed ID: 19681840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone Quality Assessment as Measured by Trabecular Bone Score in Patients With End-Stage Renal Disease on Dialysis.
    Yavropoulou MP; Vaios V; Pikilidou M; Chryssogonidis I; Sachinidou M; Tournis S; Makris K; Kotsa K; Daniilidis M; Haritanti A; Liakopoulos V
    J Clin Densitom; 2017; 20(4):490-497. PubMed ID: 28039046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.